PBAC's latest decision on Medroxyprogesterone acetate: Recommended (2023). Considered for Contraception in women, particularly in remote communities where it is a preferred form among Aboriginal and Torres Strait Islander women.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Women requiring contraception, particularly Aboriginal and Torres Strait Islander women in remote communities.
Therapy area
Women's health
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
medroxyprogesterone acetate 150 mg/mL injection, vial form
Economic model
Cost-minimisation
ICER note
No economic analysis submitted; cost-minimisation basis assessment only.